Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis
Immune checkpoint inhibitors (ICIs) has revolutionized the treatment of different advanced solid tumors, but most patients develop severe immune-related adverse events (irAEs). Although a bi-directional crosstalk between bone and immune systems is widely described, the effect of ICIs on the skeleton...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-12-01
|
| Series: | Journal of Bone Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2212137422000495 |
| _version_ | 1811201684905394176 |
|---|---|
| author | Francesco Pantano Flavia Tramontana Michele Iuliani Giulia Leanza Sonia Simonetti Alessandra Piccoli Annalisa Paviglianiti Alessio Cortellini Gian Paolo Spinelli Umile Giuseppe Longo Rocky Strollo Bruno Vincenzi Giuseppe Tonini Nicola Napoli Daniele Santini |
| author_facet | Francesco Pantano Flavia Tramontana Michele Iuliani Giulia Leanza Sonia Simonetti Alessandra Piccoli Annalisa Paviglianiti Alessio Cortellini Gian Paolo Spinelli Umile Giuseppe Longo Rocky Strollo Bruno Vincenzi Giuseppe Tonini Nicola Napoli Daniele Santini |
| author_sort | Francesco Pantano |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) has revolutionized the treatment of different advanced solid tumors, but most patients develop severe immune-related adverse events (irAEs). Although a bi-directional crosstalk between bone and immune systems is widely described, the effect of ICIs on the skeleton is poorly investigated. Here, we analyze the changes in plasma levels of type I collagen C-terminal telopeptide (CTX-I) and N-terminal propeptide of type I procollagen (PINP), reference makers of bone turnover, in patients treated with ICIs and their association with clinical outcome.A series of 44 patients affected by advanced non-small cell lung cancer or renal cell carcinoma, without bone metastases, and treated with ICIs as monotherapy were enrolled. CTX-I and PINP plasma levels were assessed at baseline and after 3 months of ICIs treatment by ELISA kits.A significant increase of CTX-I with a concomitant decreasing trend towards the reduction of PINP was observed after 3 months of treatment. Intriguingly, CTX-I increase was associated with poor prognosis in terms of treatment response and survival. These data suggest a direct relationship between ICIs treatment, increased osteoclast activity and potential fracture risk.Overall, this study reveals that ICIs may act as triggers for skeletal events, and if confirmed in larger prospective studies, it would identify a new class of skeletal-related irAEs. |
| first_indexed | 2024-04-12T02:25:44Z |
| format | Article |
| id | doaj.art-865a61b61880464a85ab7ba95e4c53fd |
| institution | Directory Open Access Journal |
| issn | 2212-1374 |
| language | English |
| last_indexed | 2024-04-12T02:25:44Z |
| publishDate | 2022-12-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of Bone Oncology |
| spelling | doaj.art-865a61b61880464a85ab7ba95e4c53fd2022-12-22T03:52:00ZengElsevierJournal of Bone Oncology2212-13742022-12-0137100459Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysisFrancesco Pantano0Flavia Tramontana1Michele Iuliani2Giulia Leanza3Sonia Simonetti4Alessandra Piccoli5Annalisa Paviglianiti6Alessio Cortellini7Gian Paolo Spinelli8Umile Giuseppe Longo9Rocky Strollo10Bruno Vincenzi11Giuseppe Tonini12Nicola Napoli13Daniele Santini14Medical Oncology Department, Campus Bio-Medico University of Rome, Rome, ItalyDepartment of Medicine, Unit of Endocrinology and Diabetes, Università Campus Bio-Medico di Roma, Rome, ItalyMedical Oncology Department, Campus Bio-Medico University of Rome, Rome, Italy; Corresponding author.Department of Medicine, Unit of Endocrinology and Diabetes, Università Campus Bio-Medico di Roma, Rome, ItalyMedical Oncology Department, Campus Bio-Medico University of Rome, Rome, ItalyDepartment of Medicine, Unit of Endocrinology and Diabetes, Università Campus Bio-Medico di Roma, Rome, ItalyDepartment of Medicine, Unit of Endocrinology and Diabetes, Università Campus Bio-Medico di Roma, Rome, Italy; Hematology Department, Institut Català d’Oncologia Hospitalet, Barcelona, Spain; Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona, SpainMedical Oncology Department, Campus Bio-Medico University of Rome, Rome, ItalyUOC Oncologia Universitaria, Sapienza University of Rome- Polo Pontino, ItalyDepartment of Orthopaedic and Trauma Surgery, Campus Bio-Medico University of Rome, Rome, ItalyDipartimento di Scienze e Tecnologie per l'Uomo e l'Ambiente, Università Campus Bio-Medico di Roma, Rome, ItalyMedical Oncology Department, Campus Bio-Medico University of Rome, Rome, ItalyMedical Oncology Department, Campus Bio-Medico University of Rome, Rome, ItalyDepartment of Medicine, Unit of Endocrinology and Diabetes, Università Campus Bio-Medico di Roma, Rome, ItalyMedical Oncology Department, Campus Bio-Medico University of Rome, Rome, Italy; UOC Oncologia Universitaria, Sapienza University of Rome- Polo Pontino, ItalyImmune checkpoint inhibitors (ICIs) has revolutionized the treatment of different advanced solid tumors, but most patients develop severe immune-related adverse events (irAEs). Although a bi-directional crosstalk between bone and immune systems is widely described, the effect of ICIs on the skeleton is poorly investigated. Here, we analyze the changes in plasma levels of type I collagen C-terminal telopeptide (CTX-I) and N-terminal propeptide of type I procollagen (PINP), reference makers of bone turnover, in patients treated with ICIs and their association with clinical outcome.A series of 44 patients affected by advanced non-small cell lung cancer or renal cell carcinoma, without bone metastases, and treated with ICIs as monotherapy were enrolled. CTX-I and PINP plasma levels were assessed at baseline and after 3 months of ICIs treatment by ELISA kits.A significant increase of CTX-I with a concomitant decreasing trend towards the reduction of PINP was observed after 3 months of treatment. Intriguingly, CTX-I increase was associated with poor prognosis in terms of treatment response and survival. These data suggest a direct relationship between ICIs treatment, increased osteoclast activity and potential fracture risk.Overall, this study reveals that ICIs may act as triggers for skeletal events, and if confirmed in larger prospective studies, it would identify a new class of skeletal-related irAEs.http://www.sciencedirect.com/science/article/pii/S2212137422000495Type I Collagen C-Terminal Telopeptide (CTX-I)N-terminal propeptide of type I procollagen (PINP)Immune checkpoint inhibitors (ICIs)Bone health |
| spellingShingle | Francesco Pantano Flavia Tramontana Michele Iuliani Giulia Leanza Sonia Simonetti Alessandra Piccoli Annalisa Paviglianiti Alessio Cortellini Gian Paolo Spinelli Umile Giuseppe Longo Rocky Strollo Bruno Vincenzi Giuseppe Tonini Nicola Napoli Daniele Santini Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis Journal of Bone Oncology Type I Collagen C-Terminal Telopeptide (CTX-I) N-terminal propeptide of type I procollagen (PINP) Immune checkpoint inhibitors (ICIs) Bone health |
| title | Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis |
| title_full | Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis |
| title_fullStr | Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis |
| title_full_unstemmed | Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis |
| title_short | Changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors: An exploratory analysis |
| title_sort | changes in bone turnover markers in patients without bone metastases receiving immune checkpoint inhibitors an exploratory analysis |
| topic | Type I Collagen C-Terminal Telopeptide (CTX-I) N-terminal propeptide of type I procollagen (PINP) Immune checkpoint inhibitors (ICIs) Bone health |
| url | http://www.sciencedirect.com/science/article/pii/S2212137422000495 |
| work_keys_str_mv | AT francescopantano changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT flaviatramontana changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT micheleiuliani changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT giulialeanza changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT soniasimonetti changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT alessandrapiccoli changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT annalisapaviglianiti changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT alessiocortellini changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT gianpaolospinelli changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT umilegiuseppelongo changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT rockystrollo changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT brunovincenzi changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT giuseppetonini changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT nicolanapoli changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis AT danielesantini changesinboneturnovermarkersinpatientswithoutbonemetastasesreceivingimmunecheckpointinhibitorsanexploratoryanalysis |